Cargando…

Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors

The aim of this study was to determine the clinical features, treatment factors, and prognosis of patients with multiple primary malignant tumors (MPMTs). In total, 161 patients with MPMTs at our hospital (The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China) were analyz...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Meng, Zhang, Xiao, Shen, Yanwei, Wang, Fan, Yang, Jiao, Wang, Biyuan, Chen, Zheling, Li, Pan, Zhang, Xiaoman, Li, Shuting, Yang, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413286/
https://www.ncbi.nlm.nih.gov/pubmed/28445321
http://dx.doi.org/10.1097/MD.0000000000006799
_version_ 1783233159644577792
author Lv, Meng
Zhang, Xiao
Shen, Yanwei
Wang, Fan
Yang, Jiao
Wang, Biyuan
Chen, Zheling
Li, Pan
Zhang, Xiaoman
Li, Shuting
Yang, Jin
author_facet Lv, Meng
Zhang, Xiao
Shen, Yanwei
Wang, Fan
Yang, Jiao
Wang, Biyuan
Chen, Zheling
Li, Pan
Zhang, Xiaoman
Li, Shuting
Yang, Jin
author_sort Lv, Meng
collection PubMed
description The aim of this study was to determine the clinical features, treatment factors, and prognosis of patients with multiple primary malignant tumors (MPMTs). In total, 161 patients with MPMTs at our hospital (The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China) were analyzed in this study. We found that among 161 patients with MPMTs, 78 (48.4%) patients had synchronous tumors and 83 (51.6%) patients had metachronous tumors. Most clinical and pathological features were similar in both groups. Most patients with MPMTs were men and older patients (>50 years old), and adenocarcinoma was the most frequent pathology type. The most frequent location of all MPMTs was the digestive system. The leading tumor association was between digestive–digestive tumors, also. However, patients with synchronous tumors and MPMTs of the digestive system showed a shorter survival time. In the metachronous cancer group, the median interval time was 60 months, and a short interval time (≤60 months) was associated with a shorter survival time. In addition, survival time was increased in the younger age group (≤50 years old) and in patients who accepted surgery-based comprehensive therapy. However, only interval time (≤60 months) was an independent prognostic factor associated with survival for the metachronous cancer group. Therefore, careful surveillance and follow-up are especially important in these patients.
format Online
Article
Text
id pubmed-5413286
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-54132862017-05-05 Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors Lv, Meng Zhang, Xiao Shen, Yanwei Wang, Fan Yang, Jiao Wang, Biyuan Chen, Zheling Li, Pan Zhang, Xiaoman Li, Shuting Yang, Jin Medicine (Baltimore) 4400 The aim of this study was to determine the clinical features, treatment factors, and prognosis of patients with multiple primary malignant tumors (MPMTs). In total, 161 patients with MPMTs at our hospital (The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China) were analyzed in this study. We found that among 161 patients with MPMTs, 78 (48.4%) patients had synchronous tumors and 83 (51.6%) patients had metachronous tumors. Most clinical and pathological features were similar in both groups. Most patients with MPMTs were men and older patients (>50 years old), and adenocarcinoma was the most frequent pathology type. The most frequent location of all MPMTs was the digestive system. The leading tumor association was between digestive–digestive tumors, also. However, patients with synchronous tumors and MPMTs of the digestive system showed a shorter survival time. In the metachronous cancer group, the median interval time was 60 months, and a short interval time (≤60 months) was associated with a shorter survival time. In addition, survival time was increased in the younger age group (≤50 years old) and in patients who accepted surgery-based comprehensive therapy. However, only interval time (≤60 months) was an independent prognostic factor associated with survival for the metachronous cancer group. Therefore, careful surveillance and follow-up are especially important in these patients. Wolters Kluwer Health 2017-04-28 /pmc/articles/PMC5413286/ /pubmed/28445321 http://dx.doi.org/10.1097/MD.0000000000006799 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 4400
Lv, Meng
Zhang, Xiao
Shen, Yanwei
Wang, Fan
Yang, Jiao
Wang, Biyuan
Chen, Zheling
Li, Pan
Zhang, Xiaoman
Li, Shuting
Yang, Jin
Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors
title Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors
title_full Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors
title_fullStr Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors
title_full_unstemmed Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors
title_short Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors
title_sort clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors
topic 4400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413286/
https://www.ncbi.nlm.nih.gov/pubmed/28445321
http://dx.doi.org/10.1097/MD.0000000000006799
work_keys_str_mv AT lvmeng clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors
AT zhangxiao clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors
AT shenyanwei clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors
AT wangfan clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors
AT yangjiao clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors
AT wangbiyuan clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors
AT chenzheling clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors
AT lipan clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors
AT zhangxiaoman clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors
AT lishuting clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors
AT yangjin clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors